Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) and programmed cell death ligand-1 (PD-L1) inhibition in this disease. In this study, the combination of savoliti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2023-05, Vol.41 (14), p.2493-2502
Hauptverfasser:	Suárez, Cristina, Larkin, James M G, Patel, Poulam, Valderrama, Begoña P, Rodriguez-Vida, Alejo, Glen, Hilary, Thistlethwaite, Fiona, Ralph, Christy, Srinivasan, Gopalakrishnan, Mendez-Vidal, Maria Jose, Hartmaier, Ryan, Markovets, Aleksandra, Prendergast, Aaron, Szabados, Bernadett, Mousa, Kelly, Powles, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects B7-H1 Antigen Humans Kidney Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!